Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANDERSON MEHRLE

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1396788022
CMS profile
18164
Location
BARTLESVILLE, OK

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$13,560.54

55 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANDERSON MEHRLE

NPI 1396788022 · CMS profile ID 18164

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

BARTLESVILLE, OK

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1396788022?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANDERSON MEHRLE, NPI 1396788022, CMS profile ID 18164. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1396788022?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). ANDERSON MEHRLE, NPI 1396788022, CMS profile ID 18164. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1396788022?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
ANDERSON MEHRLE, NPI 1396788022, CMS profile ID 18164, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1396788022?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

55 matching records · $13,560.54 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 55 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–55 of 55.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Abbott Laboratories $25.1203/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818431859 CMS
Medtronic, Inc. $15.6003/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815595199 CMS
Medtronic, Inc. $90.8502/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815578743 CMS
Medtronic, Inc. $53.8901/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815571651 CMS
Medtronic, Inc. $110.4501/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815548603 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,866.22 57
PY2020 $1,950.39 39
PY2021 $13,560.54 55
PY2022 $17,479.01 36
PY2023 $16,165.88 72
PY2024 $20,860.45 89
PY2025 $55,302.99 129

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $245,485.54 84
PY2024 Principal investigator $301,840.67 101
PY2023 Principal investigator $258,638.42 65
PY2022 Principal investigator $134,410.45 46
PY2021 Principal investigator $480,969.10 52
PY2020 Principal investigator $54,867.04 5
PY2019 Principal investigator $35,280.00 10

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

84 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Abbott Laboratories $354.00 12/19/2025 Non-covered Recipient Entity
WCG Clinical, Inc
NCT04370691--JETi Lower Extremity Arterial Thrombosis No dispute reported 06/30/2026 1248160946
Principal investigator 1 Abbott Laboratories $624.00 12/19/2025 Non-covered Recipient Entity
WCG Clinical, Inc
NCT04370691--JETi Lower Extremity Arterial Thrombosis No dispute reported 06/30/2026 1248160952
Principal investigator 1 Abbott Laboratories $400.00 12/19/2025 Non-covered Recipient Entity
ST John Health System Inc
NCT04227899--LIFE-BTK Randomized Controlled Trial No dispute reported 06/30/2026 1248160954
Principal investigator 1 Janssen Research & Development, LLC $5,798.00 12/12/2025 Non-covered Recipient Entity
Ascension St John Medcl Ctr Admin Ofc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175262605
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,805.73 12/03/2025 Non-covered Recipient Entity
St John Providence Health System Home Care
REDEFINE-HF Study #22438 No dispute reported 06/30/2026 1225419047
Principal investigator 1 Abbott Laboratories $6,494.00 11/26/2025 Non-covered Recipient Entity
ST John Health System Inc
NCT04370691--JETi Lower Extremity Arterial Thrombosis No dispute reported 06/30/2026 1248159964
Principal investigator 1 Abbott Laboratories $1,500.00 11/26/2025 Non-covered Recipient Entity
ST John Health System Inc
NCT06656364--Esprit BTK Post-Approval Study No dispute reported 06/30/2026 1248160072
Principal investigator 1 Shockwave Medical, Inc $1,000.00 11/24/2025 Non-covered Recipient Entity
St John Physicians Inc.
Prospective, Multi-center, Single-arm Study of the Shockwave Medical Peripheral Intravascular Lithotripsy (IVL) System for Treatment of Calcified Peripheral Arterial Disease (PAD) in Below-the-Knee (BTK) Arteries No dispute reported 06/30/2026 1175055816
Principal investigator 1 Abbott Laboratories $753.00 11/21/2025 Non-covered Recipient Entity
WCG Clinical, Inc
NCT06656364--Esprit BTK Post-Approval Study No dispute reported 06/30/2026 1248159702
Principal investigator 1 Janssen Research & Development, LLC $1,997.00 11/19/2025 Non-covered Recipient Entity
Ascension St John Medcl Ctr Admin Ofc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175262738
Principal investigator 1 Abbott Laboratories $1,006.00 11/14/2025 Non-covered Recipient Entity
WCG Clinical, Inc
NCT06656364--Esprit BTK Post-Approval Study No dispute reported 06/30/2026 1248159498
Principal investigator 1 Abbott Laboratories $1,500.00 11/07/2025 Non-covered Recipient Entity
ST John Health System Inc
NCT06656364--Esprit BTK Post-Approval Study No dispute reported 06/30/2026 1248159204
Principal investigator 1 Janssen Research & Development, LLC $578.00 11/03/2025 Non-covered Recipient Entity
Ascension St John Medcl Ctr Admin Ofc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175262787
Principal investigator 1 Abbott Laboratories $400.00 10/30/2025 Non-covered Recipient Entity
ST John Health System Inc
NCT04227899--LIFE-BTK Randomized Controlled Trial No dispute reported 06/30/2026 1248158840
Principal investigator 1 Abbott Laboratories $8,834.43 10/29/2025 Non-covered Recipient Entity
ST John Health System Inc
NCT06656364--Esprit BTK Post-Approval Study No dispute reported 06/30/2026 1248158800
Principal investigator 1 Janssen Research & Development, LLC $5,000.00 10/27/2025 Non-covered Recipient Entity
ST. JOHN HEALTH SYSTEM INC
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175400888
Principal investigator 1 Janssen Research & Development, LLC $516.00 10/27/2025 Non-covered Recipient Entity
ST. JOHN HEALTH SYSTEM INC
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175400917
Principal investigator 1 Abbott Laboratories $28.00 10/22/2025 Non-covered Recipient Entity
ST John Health System Inc
NCT04227899--LIFE-BTK Randomized Controlled Trial No dispute reported 06/30/2026 1248158490
Principal investigator 1 Abbott Laboratories $1,500.00 10/21/2025 Non-covered Recipient Entity
ST John Health System Inc
NCT04370691--JETi Lower Extremity Arterial Thrombosis No dispute reported 06/30/2026 1248158310
Principal investigator 1 Abbott Laboratories $2,000.00 10/21/2025 Non-covered Recipient Entity
ST John Health System Inc
NCT04370691--JETi Lower Extremity Arterial Thrombosis No dispute reported 06/30/2026 1248158332
Principal investigator 1 Abbott Laboratories $3,500.00 10/21/2025 Non-covered Recipient Entity
ST John Health System Inc
NCT04370691--JETi Lower Extremity Arterial Thrombosis No dispute reported 06/30/2026 1248158350
Principal investigator 1 Janssen Research & Development, LLC $516.00 10/17/2025 Non-covered Recipient Entity
Ascension St John Medcl Ctr Admin Ofc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175263051
Principal investigator 1 Philips North America LLC $3,380.32 10/07/2025 Non-covered Recipient Entity
ASCENSION ST JOHN
THOR IDE No dispute reported 06/30/2026 1232579107
Principal investigator 1 Abbott Laboratories $169.00 10/02/2025 Non-covered Recipient Entity
WCG Clinical, Inc
NCT06656364--Esprit BTK Post-Approval Study No dispute reported 06/30/2026 1248158042
Principal investigator 1 Abbott Laboratories $2,090.00 10/02/2025 Non-covered Recipient Entity
WCG Clinical, Inc
NCT06656364--Esprit BTK Post-Approval Study No dispute reported 06/30/2026 1248158050
Principal investigator 1 Abbott Laboratories $792.00 09/25/2025 Non-covered Recipient Entity
WCG Clinical, Inc
NCT06656364--Esprit BTK Post-Approval Study No dispute reported 06/30/2026 1248156866
Principal investigator 1 Janssen Research & Development, LLC $8,514.00 09/19/2025 Non-covered Recipient Entity
Ascension St John Medcl Ctr Admin Ofc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175262707
Principal investigator 1 Philips North America LLC $3,380.32 09/19/2025 Non-covered Recipient Entity
ASCENSION ST JOHN
THOR IDE No dispute reported 06/30/2026 1232579109
Principal investigator 1 Philips North America LLC $3,380.32 09/19/2025 Non-covered Recipient Entity
ASCENSION ST JOHN
THOR IDE No dispute reported 06/30/2026 1232579117
Principal investigator 1 Janssen Research & Development, LLC $2,314.00 09/05/2025 Non-covered Recipient Entity
Ascension St John Medcl Ctr Admin Ofc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175262769
Principal investigator 1 Abbott Laboratories $149.94 08/26/2025 Non-covered Recipient Entity
ST John Health System Inc
NCT06656364--Esprit BTK Post-Approval Study No dispute reported 06/30/2026 1248157204
Principal investigator 1 Janssen Research & Development, LLC $2,626.00 08/25/2025 Non-covered Recipient Entity
Ascension St John Medcl Ctr Admin Ofc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175262846
Principal investigator 1 Abbott Laboratories $7,522.94 08/18/2025 Non-covered Recipient Entity
ST John Health System Inc
NCT06656364--Esprit BTK Post-Approval Study No dispute reported 06/30/2026 1248155586
Principal investigator 1 Abbott Laboratories $1,500.00 08/12/2025 Non-covered Recipient Entity
ST John Health System Inc
NCT06656364--Esprit BTK Post-Approval Study No dispute reported 06/30/2026 1248155418
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $500.00 08/11/2025 Non-covered Recipient Entity
St John Providence Health System Home Care
REDEFINE-HF Study #22438 No dispute reported 06/30/2026 1225419419
Principal investigator 1 Abbott Laboratories $7,522.94 07/28/2025 Non-covered Recipient Entity
ST John Health System Inc
NCT06656364--Esprit BTK Post-Approval Study No dispute reported 06/30/2026 1248153428
Principal investigator 1 Abbott Laboratories $753.00 07/24/2025 Non-covered Recipient Entity
WCG Clinical, Inc
NCT06656364--Esprit BTK Post-Approval Study No dispute reported 06/30/2026 1248153390
Principal investigator 1 Janssen Research & Development, LLC $671.00 07/14/2025 Non-covered Recipient Entity
Ascension St John Medcl Ctr Admin Ofc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175263013
Principal investigator 1 Abbott Laboratories $6,380.14 07/10/2025 Non-covered Recipient Entity
ST John Health System Inc
NCT04370691--JETi Lower Extremity Arterial Thrombosis No dispute reported 06/30/2026 1248153046
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,195.00 07/03/2025 Non-covered Recipient Entity
St John Providence Health System Home Care
REDEFINE-HF Study #22438 No dispute reported 06/30/2026 1225419225
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,000.00 06/30/2025 Non-covered Recipient Entity
St John Providence Health System Home Care
REDEFINE-HF Study #22438 No dispute reported 06/30/2026 1225419017
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,000.00 06/30/2025 Non-covered Recipient Entity
St John Providence Health System Home Care
REDEFINE-HF Study #22438 No dispute reported 06/30/2026 1225419645
Principal investigator 1 Philips North America LLC $1,200.00 06/27/2025 Non-covered Recipient Entity
ASCENSION ST JOHN
THOR IDE No dispute reported 06/30/2026 1232579039
Principal investigator 1 Abbott Laboratories $6,000.00 06/26/2025 Non-covered Recipient Entity
ST John Health System Inc
NCT04227899--LIFE-BTK Randomized Controlled Trial No dispute reported 06/30/2026 1248152176
Principal investigator 1 Abbott Laboratories $4,500.00 06/26/2025 Non-covered Recipient Entity
ST John Health System Inc
NCT04227899--LIFE-BTK Randomized Controlled Trial No dispute reported 06/30/2026 1248152180
Principal investigator 1 Janssen Research & Development, LLC $9,792.00 06/26/2025 Non-covered Recipient Entity
Ascension St John Medcl Ctr Admin Ofc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175262746
Principal investigator 1 Janssen Research & Development, LLC $7,887.00 06/20/2025 Non-covered Recipient Entity
Ascension St John Medcl Ctr Admin Ofc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175262889
Principal investigator 1 Janssen Research & Development, LLC $516.00 06/16/2025 Non-covered Recipient Entity
ST. JOHN HEALTH SYSTEM INC
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175400924
Principal investigator 1 Abbott Laboratories $2,090.00 06/05/2025 Non-covered Recipient Entity
WCG Clinical, Inc
NCT04370691--JETi Lower Extremity Arterial Thrombosis No dispute reported 06/30/2026 1248151634
Principal investigator 1 Abbott Laboratories $101.00 06/03/2025 Non-covered Recipient Entity
WCG Clinical, Inc
NCT04227899--LIFE-BTK Randomized Controlled Trial No dispute reported 06/30/2026 1248151532
Principal investigator 1 Janssen Research & Development, LLC $470.00 05/26/2025 Non-covered Recipient Entity
ST. JOHN HEALTH SYSTEM INC
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175400881
Principal investigator 1 Philips North America LLC $22,500.00 05/13/2025 Non-covered Recipient Entity
ASCENSION ST JOHN
THOR IDE No dispute reported 06/30/2026 1232579037
Principal investigator 1 Janssen Research & Development, LLC $1,800.00 05/02/2025 Non-covered Recipient Entity
Ascension St John Medcl Ctr Admin Ofc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175262911
Principal investigator 1 Abbott Laboratories $8,000.00 04/29/2025 Non-covered Recipient Entity
ST John Health System Inc
NCT06656364--Esprit BTK Post-Approval Study No dispute reported 06/30/2026 1248150190
Principal investigator 1 Abbott Laboratories $336.72 04/21/2025 Non-covered Recipient Entity
ST John Health System Inc
NCT04227899--LIFE-BTK Randomized Controlled Trial No dispute reported 06/30/2026 1248150006
Principal investigator 1 Janssen Research & Development, LLC $1,200.00 04/17/2025 Non-covered Recipient Entity
ST. JOHN HEALTH SYSTEM INC
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175400858
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $16,480.00 04/14/2025 Non-covered Recipient Entity
St John Providence Health System Home Care
REDEFINE-HF Study #22438 No dispute reported 06/30/2026 1225419487
Principal investigator 1 Shockwave Medical, Inc $479.76 04/11/2025 Non-covered Recipient Entity
St John Physicians Inc.
Prospective, Multi-center, Single-arm Study of the Shockwave Medical Peripheral Intravascular Lithotripsy (IVL) System for Treatment of Calcified Peripheral Arterial Disease (PAD) in Below-the-Knee (BTK) Arteries No dispute reported 06/30/2026 1175055840
Principal investigator 1 Janssen Research & Development, LLC $470.00 03/31/2025 Non-covered Recipient Entity
ST. JOHN HEALTH SYSTEM INC
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175400864
Principal investigator 1 Janssen Research & Development, LLC $470.00 03/31/2025 Non-covered Recipient Entity
ST. JOHN HEALTH SYSTEM INC
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175400868
Principal investigator 1 Janssen Research & Development, LLC $470.00 03/31/2025 Non-covered Recipient Entity
ST. JOHN HEALTH SYSTEM INC
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175400876
Principal investigator 1 Janssen Research & Development, LLC $470.00 03/31/2025 Non-covered Recipient Entity
ST. JOHN HEALTH SYSTEM INC
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175400905
Principal investigator 1 Janssen Research & Development, LLC $470.00 03/31/2025 Non-covered Recipient Entity
ST. JOHN HEALTH SYSTEM INC
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175400912
Principal investigator 1 Janssen Research & Development, LLC $516.00 03/28/2025 Non-covered Recipient Entity
ST. JOHN HEALTH SYSTEM INC
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175400895
Principal investigator 1 Janssen Research & Development, LLC $10,002.00 03/21/2025 Non-covered Recipient Entity
Ascension St John Medcl Ctr Admin Ofc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175262662
Principal investigator 1 Abbott Laboratories $2,090.00 03/11/2025 Non-covered Recipient Entity
WCG Clinical, Inc
NCT04227899--LIFE-BTK Randomized Controlled Trial No dispute reported 06/30/2026 1248147586
Principal investigator 1 Abbott Laboratories $169.00 03/07/2025 Non-covered Recipient Entity
WCG Clinical, Inc
NCT06656364--Esprit BTK Post-Approval Study No dispute reported 06/30/2026 1248147434
Principal investigator 1 Shockwave Medical, Inc $774.53 02/24/2025 Non-covered Recipient Entity
St John Physicians Inc.
Prospective, Multi-center, Single-arm Study of the Shockwave Medical Peripheral Intravascular Lithotripsy (IVL) System for Treatment of Calcified Peripheral Arterial Disease (PAD) in Below-the-Knee (BTK) Arteries No dispute reported 06/30/2026 1175055794
Principal investigator 1 Shockwave Medical, Inc $1,500.00 02/24/2025 Non-covered Recipient Entity
St John Physicians Inc.
Prospective, Multi-center, Single-arm Study of the Shockwave Medical Peripheral Intravascular Lithotripsy (IVL) System for Treatment of Calcified Peripheral Arterial Disease (PAD) in Below-the-Knee (BTK) Arteries No dispute reported 06/30/2026 1175055803
Principal investigator 1 Shockwave Medical, Inc $874.57 02/24/2025 Non-covered Recipient Entity
St John Physicians Inc.
Prospective, Multi-center, Single-arm Study of the Shockwave Medical Peripheral Intravascular Lithotripsy (IVL) System for Treatment of Calcified Peripheral Arterial Disease (PAD) in Below-the-Knee (BTK) Arteries No dispute reported 06/30/2026 1175055831
Principal investigator 1 Abbott Laboratories $18.98 02/21/2025 Non-covered Recipient Entity
MPX Group
NCT03507777--ILUMIEN IV: OPTIMAL Percutaneous Coronary Intervention (PCI) No dispute reported 06/30/2026 1248146776
Principal investigator 1 Janssen Research & Development, LLC $1,361.00 02/19/2025 Non-covered Recipient Entity
Ascension St John Medcl Ctr Admin Ofc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175262796
Principal investigator 1 Abbott Laboratories $4,641.90 02/17/2025 Non-covered Recipient Entity
ST John Health System Inc
NCT04370691--JETi Lower Extremity Arterial Thrombosis No dispute reported 06/30/2026 1248146658
Principal investigator 1 Janssen Research & Development, LLC $224.00 02/12/2025 Non-covered Recipient Entity
Ascension St John Medcl Ctr Admin Ofc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175262881
Principal investigator 1 Janssen Research & Development, LLC $8,000.00 02/06/2025 Non-covered Recipient Entity
ST. JOHN HEALTH SYSTEM INC
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175400900
Principal investigator 1 Janssen Research & Development, LLC $1,032.00 02/05/2025 Non-covered Recipient Entity
Ascension St John Medcl Ctr Admin Ofc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175262762
Principal investigator 1 AstraZeneca Pharmaceuticals LP $7,666.00 01/31/2025 Non-covered Recipient Entity
ST JOHN HEALTH SYSTEM - ST JOHN CLINIC
Dapagliflozin in Acute Decompensated Heart Failure No dispute reported 06/30/2026 1185539475
Principal investigator 1 Abbott Laboratories $159.00 01/24/2025 Non-covered Recipient Entity
WCG Clinical, Inc
NCT06656364--Esprit BTK Post-Approval Study No dispute reported 06/30/2026 1248145782
Principal investigator 1 Abbott Laboratories $159.00 01/24/2025 Non-covered Recipient Entity
WCG Clinical, Inc
NCT04227899--LIFE-BTK Randomized Controlled Trial No dispute reported 06/30/2026 1248145784
Principal investigator 1 Janssen Research & Development, LLC $506.00 01/24/2025 Non-covered Recipient Entity
Ascension St John Medcl Ctr Admin Ofc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175262997
Principal investigator 1 Janssen Research & Development, LLC $2,722.00 01/22/2025 Non-covered Recipient Entity
Ascension St John Medcl Ctr Admin Ofc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175263133
Principal investigator 1 Abbott Laboratories $450.00 01/20/2025 Non-covered Recipient Entity
ST John Health System Inc
NCT04227899--LIFE-BTK Randomized Controlled Trial No dispute reported 06/30/2026 1248145776
Principal investigator 1 Abbott Laboratories $1,972.00 01/15/2025 Non-covered Recipient Entity
WCG Clinical, Inc
NCT06656364--Esprit BTK Post-Approval Study No dispute reported 06/30/2026 1248144864
Principal investigator 1 Abbott Laboratories $12,000.00 01/07/2025 Non-covered Recipient Entity
ST John Health System Inc
NCT06656364--Esprit BTK Post-Approval Study No dispute reported 06/30/2026 1248144862